Sanofi unit defeats challenge to booster vaccine trademark in Europe

An EUIPO appeals board sided with the French pharma company’s vaccine division in a dispute with an India-based biotech company over Sanofi’s ‘Covaxis’ mark.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Trademarks

EUIPO hits five million TM and design applications

12 August 2025 Office says growth reflect practical advantages of registration | Companies with IP rights see 23.8% higher revenue per employee | New GI rights and more AI assistance with applications planned.

Patents

WATCH: Section 112 – Where has the dust settled?

23 June 2025 David Gindler of Orrick discusses the US Supreme Court’s ruling in Amgen v. Sanofi and what it means for ongoing Section 112 litigation. The session considers how the decision has been applied – and how it may continue to be applied – by the Federal Circuit, district courts, and the PTAB, with a focus on its relevance to the life sciences sector.

LVMH: ‘External counsel must simplify, not complicate’

Too busy to save time? Why IP teams can’t afford to wait on AI

Birkenstock lands key win over sandal designs—defying German ruling

‘Instrumental’ IP law firm group CEO to retire after 30 years

German court rules against OpenAI in copyright first

Oracle counsel warns: Beware the ‘Streisand effect’ in disputes

Stanley cup maker accuses US retailer of ‘parasitic copying’

Morgan Lewis expands litigation team in Seattle

Sanofi unit defeats challenge to booster vaccine trademark in Europe

More on this story

Editor's picks

Editor's picks

More articles